- HIV AIDS Myths and Facts Slideshow Pictures
- Take the HIV/AIDS Quiz
- AIDS Retrospective Slideshow Pictures
- HIV-AIDS FAQs
- Patient Comments: Human Immunodeficiency Virus (HIV, AIDS) - Symptoms
- Patient Comments: Human Immunodeficiency Virus (HIV) - Risk Factors and Transmission
- Find a local Infectious Disease Specialist in your town
- Human immunodeficiency virus (HIV) facts
- What is the history of HIV, and when was HIV discovered?
- What tests are used in the diagnosis of HIV?
- How is HIV spread (transmitted)?
- What are symptoms and signs of HIV infection and AIDS in men, women, and children?
- What happens after an exposure to the blood or genital secretions of an HIV-infected person?
- What laboratory tests are used to monitor HIV-infected people?
- What are HIV treatments and medications? What are the key principles in managing HIV infection?
- When should antiviral therapy be started?
- What is the initial therapy for HIV?
- What are nucleoside and nucleotide analogue reverse transcriptase inhibitors (NRTIs)?
- What are nonnucleoside analogue reverse transcriptase inhibitors (NNRTIs)?
- What are protease inhibitors?
- What are fusion inhibitors?
- What is a CCR5 antagonist?
- What is an integrase strand transfer inhibitor?
- What HIV drugs are in development?
- What are side effects of HIV therapy?
- What happens if the patient's viral load increases while on HIV therapy?
- What are the risks of missing doses or stopping antiviral therapy?
- Should patients with the flu- or mono-like illness of primary HIV infection be treated?
- What about treatment for HIV during pregnancy?
- What can be done for people who have severe immunosuppression?
- What is the future for HIV-infected individuals with regards to treatment simplification and cure research?
- What is in the future for preventing HIV transmission?
Quick GuideHIV AIDS Pictures Slideshow: Myths and Facts on Symptoms and Treatments
What are fusion inhibitors?
A fusion inhibitor blocks an early step in the viral life cycle. Enfuvirtide (Fuzeon, T-20) attaches to the envelope surrounding the virus and prevents it from entering the CD4 cells. This prevents the infection of CD4 cells by HIV. T-20 is the first approved drug in this class. It is given as a twice-daily subcutaneous injection (90 mg). It is used primarily in individuals who have developed resistance to other classes of drugs in order to create a new potent combination. Like all other antivirals, it is most useful in those taking other active drugs at the same time in order to optimize the chance of getting viral loads to undetectable levels and to prevent the development of drug resistance.
What is a CCR5 antagonist?
The only available drug in this class is called maraviroc (Selzentry, MVC), which is now approved for use in combination therapy in treatment-experienced and naïve patients who do not have detectable CXCR4-using virus as determined by a tropism assay. This is a unique drug in a new class that blocks viral entry by interacting with the CCR5 molecule on the surface of the CD4 cell. It is known that HIV first binds to the CD4 molecule on the surface of CD4 cells and then connects with the CCR5 or CXCR4 molecule. Only after this second step is the virus able to enter the cell. The CCR5 antagonist prevents viruses that use CCR5 from getting into the cell. What is unique about this drug compared to others is that 20%-50% of patients have viruses that are able to use the CXCR4 receptor. In these cases, CCR5 antagonists do not appear to be active at suppressing virus. Therefore, in order to know if the drug will work for a given patient, a new test needs to be performed, the so-called tropism assays. This test will tell the provider and patient whether there is virus that uses CXCR4, in which case the patient would not be a candidate for MVC, or if they only have viruses that use CCR5, in which case MVC should be an active drug. Without tropism results, it is impossible to know whether MVC will be an active drug for a given patient.
MVC is typically dosed at either 300 mg or 150 mg twice daily, depending upon what other drugs it is given with. If the patient is taking any RTV, then they would usually receive the 150 mg dose. If RTV is not being used as part of the regimen, they would generally receive the 300 mg dose and sometimes even higher if it is being used with drugs like ETR. HIV providers are aware that whenever using any anti-HIV medications attention must be given to possible drug interactions.
What is an integrase strand transfer inhibitor?
The first available drug in this class was RAL, which is very potent at suppressing HIV in all patients who have never been on this drug or others in the class. It was initially approved for treatment-experienced patients with drug-resistant virus. It is also now approved for those starting therapy for the first time. The approved dose of RAL is 400 mg twice daily. As noted above, a second drug in this class, EVG, is approved for use as first-line therapy as part of the fixed-dose combination pill of TDF/FTC/COBI/EVG and more recently TAF/FTC/COBI/EVG as a stand-alone drug for use in treatment-experienced patients combining it with a ritonavir-boosted PI. This drug is well tolerated and given as one pill per day, but unlike RAL it does need to be taken with food and it has interactions with other drugs since it must be used with RTV or COBI, so it must be used with caution in those on multiple medications. The most recently approved antiretroviral is the InSTI DTG that is currently recommended for those starting therapy for the first time with either TDF/FTC or ABC/3TC and is available as a fixed-dose combination of ABC/3TC/DTG that can be given as a single pill per day. This drug has a limited number of drug-drug interactions and is generally well tolerated.
|RAL, raltegravir; EVG, elvitegravir; DTG, dolutegravir. 1Currently, it is approved as part of the fixed-dose combination pill of EVG (150 mg)/COBI (150 mg)/FTC (200 mg) with either TDF (300 mg) or TAF (25 mg). 2DTG must be given twice per day in patients with history of InSTI resistance.|
|Dose in each pill (mg)||200||150||502|
|Schedule||1 twice a day||1 per day||1 per day|
|Meal restrictions||None||With food||None|
There are now five approved combination pills that allow for a full regimen to be taken as a single pill once per day, so called single tablet regiments. This includes the following NRTI plus third drug combinations:
- TDF/FTC/EFV (300/200/600 mg) as Atripla
- TDF/FTC/RPV (300/200/25 mg) as Complera
- TDF/FTC/EVG/COBI (300/200/150/150 mg) as Stribild
- TAF/FTC/EVG/COBI (25/200/150/150 mg) as Genvoya
- ABC/3TC/DTG (600/300/50 mg) as Triumeq
What HIV drugs are in development?
There are many drugs currently in development that may simplify therapy and provide important options for those who have developed extensive drug resistance. Drugs that show promise in early clinical trials are often made available by the manufacturer to certain individuals with approval of the FDA. In particular, these drugs are used in individuals who are no longer responding or able to tolerate currently available agents. The next drugs likely to be approved for use will be TAF as part of fixed-dose combination with FTC and with FTC and RPV. There is also a new NNRTI, doravirine, in late-stage development for treatment naïve patients in combination with NRTIs. Novel treatment strategies are also being pursued in the form of a long-acting injectable formulation or RPV in development along with a long-acting new InSTI called cabotegravir (CAB). An early stage study showed that the combination of short-acting RPV and CAB was able to maintain virologic suppression in those with suppressed viral load. A follow-up study will soon be reported to assess whether the long-acting formulations of these drugs can be used in combination either every two or three months to maintain viral suppression in those who already have undetectable viral load. Other drugs in earlier stages of development would include new agents in new classes that either block viral maturation of attachment to the cell.